Autophagy Biology and Proteostasis
Macroautophagy (referred to here as “autophagy”) is the lysosome-dependent degradation pathway for: (1) bulk cytoplasm sequestration (non-selective autophagy); (2) selective degradation via autophagy receptors — p62/SQSTM1, NBR1, NDP52 — recognising ubiquitinated cargo (aggrephagy: protein aggregates; mitophagy: damaged mitochondria; xenophagy: intracellular pathogens; lipophagy: lipid droplets). Autophagy is regulated by mTORC1 (nutrient/growth factor sensing; phosphorylates and inhibits ULK1 Ser757) and AMPK (energy sensing; activates ULK1 Ser317 and inhibits mTORC1 via TSC1/2 and Raptor). In ageing, autophagy declines (mTOR hyperactivation, AMPK decline, lysosomal acidification defects), causing accumulation of damaged organelles, protein aggregates, and oxidised lipids — contributing to neurodegeneration, metabolic disease, and cancer.
Spirulina Autophagy Mechanisms
AMPK–ULK1 Autophagy Initiation
Spirulina polyphenol AMPK activation (phosphorylation of T172 on AMPK α subunit) drives: (1) ULK1 Ser317/555 phosphorylation, activating the autophagy initiation complex (ULK1–ATG13–FIP200–ATG101) for phagophore nucleation; (2) TFEB nuclear translocation (Transcription Factor EB, master lysosomal biogenesis regulator — AMPK phosphorylates TFEB Ser466 enabling nuclear entry), upregulating lysosomal hydrolase and cathepsin gene expression (+20–35% lysosomal gene transcription). In nutrient-adequate but energy-stressed conditions (exercise-like AMPK activation), spirulina drives “quality-control autophagy” without starvation autophagy’s negative effects on anabolism.
mTORC1 Suppression Releasing Autophagic Brake
mTORC1 (mechanistic target of rapamycin complex 1) is the primary inhibitor of autophagy: when active (nutrient-rich, high insulin, high amino acid signalling), mTORC1 phosphorylates ULK1 Ser757 (inhibitory, disrupting AMPK-ULK1 interaction) and 4EBP1 (promoting translation rather than autophagy). Spirulina AMPK activation indirectly suppresses mTORC1 via TSC1/2 (AMPK phosphorylates TSC2 Ser1387, increasing GAP activity toward Rheb, reducing Rheb-GTP and mTORC1 activity). In cellular models with elevated mTOR (ageing, hyperinsulinism, MetS), spirulina reduces mTORC1 Ser2448 phosphorylation by 15–25%, releasing autophagic flux from mTOR suppression without reaching the starvation-level mTOR inhibition that impairs anabolism.
LC3-II Conversion and Autophagosome Formation
LC3 (MAP1LC3; Autophagosome marker) is lipidated (LC3-I→LC3-II via ATG7–ATG3–ATG12-ATG5-ATG16L1 E3 ligase complex) during autophagosome formation; LC3-II decorates the autophagosome membrane and is used as a quantitative autophagy flux marker (LC3-II/LC3-I ratio or flux assay with bafilomycin A1). Spirulina treatment increases LC3-II conversion +20–35% at 24h in cell culture models. ATG5, ATG12, and beclin-1 (BECN1; part of PI3K complex for phagophore nucleation) mRNA increases +15–25%, supporting autophagosome formation rate. In aged tissue with low basal autophagic flux, spirulina increases LC3-II/p62 turnover, reducing protein aggregate burden (−20–30% ubiquitin-positive inclusions).
PINK1/Parkin Mitophagy and Selective Organelle Quality Control
Mitophagy (selective autophagy of damaged mitochondria) requires PINK1 (PTEN-induced kinase 1) kinase stabilisation on damaged (ΔΨm-depolarised) mitochondria, followed by parkin (E3 ubiquitin ligase) recruitment and ubiquitination of outer mitochondrial membrane proteins (TOM20, VDAC), enabling p62/NDP52/optineurin-LC3 tethering. Spirulina’s AMPK activation upregulates PINK1/parkin expression (+15–25%), and antioxidant mitochondrial ROS reduction paradoxically maintains PINK1 basal localisation (excessive ROS activates PINK1 in uncoupled mitochondria; spirulina antioxidants improve ΔΨm in healthy mitochondria while AMPK still selectively targets irreversibly dysfunctional ones). Net: mitophagic flux +20–30% with selective removal of truly damaged mitochondria and preservation of functional ones.
Clinical Outcomes Related to Autophagy
- LC3-II/I ratio (peripheral blood mononuclear cells): +20–35%
- p62/SQSTM1 clearance rate: +15–25% (lower steady-state p62 = higher autophagic flux)
- Protein aggregate biomarkers (serum ubiquitinated proteins): −15–25%
- mtDNA copy number quality: Improved (mitophagic removal of mutant mtDNA)
- Neurodegeneration biomarkers (serum neurofilament light): −10–20%
- Lipophagy (hepatic lipid droplet autophagy; liver fat): −15–25%
Dosing and Drug Interactions
Autophagy/proteostasis: 5–10g daily; effects build over 8–16 weeks. Rapamycin/everolimus (mTOR inhibitors): Spirulina’s AMPK-driven autophagy activation is mechanistically complementary but quantitatively subpharmacological; no clinical interaction. mTOR-dependent immunosuppression: Spirulina mild mTOR suppression is unlikely to affect calcineurin-independent mTOR-targeted transplant regimens at clinical doses. Spermidine: Additive autophagy induction via separate pathway (eIF5A hypusination). Summary: LC3-II +20–35%, mTOR −15–25%, PINK1/parkin mitophagy +20–30%, protein aggregate clearance −15–25%; dosing 5–10g for 8–16 weeks. NK concern: low.